Loading
A phase 3 trial testing Abexinostat in renal cell carcinoma, now recruiting.
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) is a phase 3 interventional study registered as NCT03592472, led by Xynomic Pharmaceuticals, and recruiting on the registry. Official title: A Randomised, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma(RENAVIV). Planned enrolment is 413 participants (estimated). The study started in 2018-07-17 and primary completion is expected in 2026-12-30. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Xynomic Pharmaceuticals, Abexinostat.
Shares Xynomic Pharmaceuticals, Abexinostat.
Shares Xynomic Pharmaceuticals, Abexinostat.
Shares Xynomic Pharmaceuticals, Abexinostat.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/